Baseline use of proton pump inhibitors and antibiotics significantly reduces progression-free and overall survival in unresectable stage III NSCLC patients treated with durvalumab, with hazard ratios up to 1.66.
- Open access
- 7 cites
The Lancet Oncology
Elsevier BV · Clinical Medicine · ISSN 1470-2045, 1474-5488
- Impact (2-yr)
- 12.2
- h-index
- 524
- Open access
- 19%
- Works
- 12.2K
- Papers this month
- 56
Rebuilt
Moved this week
Switching to camizestrant at ESR1 mutation emergence during first-line therapy significantly extends progression-free survival in hormone receptor-positive advanced breast cancer, with a median of 16.8 months.
- 8 cites
Access to cancer genomics and precision oncology remains profoundly unequal worldwide, limiting benefits for millions of patients and hindering research progress.
- 10 cites
Latest in Lancet Oncol
Newest first · last 60 days
Expanding cancer susceptibility testing to the general population requires careful evaluation of clinical and public health benefits, with evidence supporting its use mainly for well-established genes.
- 1 cites
Extended induction and consolidation therapy with daratumumab-based regimens significantly improve 5-year progression-free and overall survival in high-risk multiple myeloma patients, with median PFS not reached.
Higher microbial diversity and immunostimulatory pathways in the gut microbiome are linked to improved immune checkpoint inhibitor responses in cancer patients.
Hypofractionated postmastectomy radiotherapy is non-inferior to conventional radiotherapy in 10-year locoregional control for high-risk breast cancer patients, with similar safety profiles.
Access to cancer genomics and precision oncology remains profoundly unequal worldwide, limiting benefits for millions of patients and hindering research progress.
- 10 cites
The CPI2 prognostic model, using 14 clinical parameters, outperforms the IMDC model with 0.72 discriminative accuracy in metastatic clear cell renal cell carcinoma.
Cancer caused 1.54 million incident cases and 923,000 deaths in Africa in 2023, with a significant rise in burden since 1990, especially among young populations.
The STAMINA lifestyle intervention significantly improved quality of life and fatigue in men with prostate cancer on ADT, with FACT-P scores increasing by 4.5 points and FACIT-F by 1.9 points.
Infections caused 2.3 million new cancer cases in 2024, representing 12% of all global cancers, with Helicobacter pylori and HPV being the leading agents.
Weekly patient-reported outcome symptom monitoring increased median overall survival by 5 months in lung cancer patients across stages I-IV in a real-world setting.
Pembrolizumab plus chemotherapy followed by pembrolizumab-olaparib maintenance significantly improves progression-free survival in patients with advanced BRCA non-mutated epithelial ovarian cancer, with a hazard ratio of 0.66.
Wildfire-related PM2.5 significantly increases mortality risk in older lung cancer patients, with each 1-μg/m3 rise linked to a 7.8% higher death rate.
Follow Lancet Oncol in the app
Browse JClub
Journals this month
- bioRxiv5569
- medRxiv1746
- Environ Res483
- PNAS463
- Sci Adv439
- JAMA255
- Cell Rep210
- BMJ199
- Nat Commun177
- Environ Pollution170
- Lancet149
- Science138
- NEJM119
- Applied & Environ Microbio116
- J Exp Bot115
- Curr Biol112
- mBio109
- Nature104
Moving areas, week to 3 Oct 2026
- Single-cell and spatial transcriptomics10
- Artificial Intelligence in Healthcare and Education8
- CAR-T cell therapy research7
- Neuroinflammation and Neurodegeneration Mechanisms6
- Lung Cancer Treatments and Mutations5
- Diabetes Treatment and Management4
- Pancreatic and Hepatic Oncology Research4
- Photosynthetic Processes and Mechanisms4
- Genomics and Chromatin Dynamics4
- Gut microbiota and health4